Skip to main content
. Author manuscript; available in PMC: 2022 Mar 19.
Published in final edited form as: Circ Res. 2021 Feb 3;128(6):723–737. doi: 10.1161/CIRCRESAHA.120.317146

Figure 5. MFAP4 is sufficient to prevent phenylephrine-driven cardiomyocyte hypertrophy.

Figure 5.

A. Representative images of neonatal rat cardiomyocytes treated with BSA control or recombinant MFAP4 (rMFAP4) plus vehicle (Veh) or phenylephrine (PE). Staining shows a-actinin (green). Scale bar, 50 μm. B. Quantification of cardiomyocyte area in the indicated groups (n=100). (Two-way ANOVA results: BSA vs rMFAP4 #p=0.0001; BSA vs BSA PE *p=0.000000012; rMFAP4 vs rMFAP4 PE *p=0.0058; BSA PE vs rMFAP4 PE #p=0.000000000052.) C. qPCR analysis of hypertrophic gene expression relative to Rpl7 in the indicated groups (n=3). (Two-way ANOVA results for - Nppa: BSA vs BSA PE *p=0.0150; BSA PE vs rMFAP4 PE #p=0.0454. - Nppb: BSA vs BSA PE *p=0.0014; rMFAP4 vs rMFAP4 PE *p=0.0219; BSA PE vs rMFAP4 PE #p=0.0249. - Acta1: BSA vs rMFAP4 p=0.0619; BSA vs BSA PE *p=0.00014; rMFAP4 vs rMFAP4 PE *p=0.0050; BSA PE vs rMFAP4 PE #p=0.00058).